Healthcare
Earlybird sells BMEYE for €32.5m
Earlybird has sold Dutch medical diagnostics company BMEYE to Edwards Lifescience Corporation for €32.5m, reaping a 26% IRR on its investment.
HTGF and STIFT invest in JeNaCell
High-Tech Gründerfonds (HTGF) and The Thüringen Foundation for Technology Innovation and Research (STIFT) have invested €700,000 in German biomaterial developer JeNaCell.
Aeris Capital et al. invest in Affimed Therapeutic series-D
Aeris Capital and existing investors have backed German biotech company Affimed Therapeutic in a €15.5m series-D round.
YFM sells Primal Pictures to Informa
YFM Equity Partners has sold Primal Pictures, a publisher of medically accurate 3D models of the human anatomy, to Informa UK, a subsidiary of the international publishing and events business Informa Group.
August sells Enara for £111m
August Equity has sold UK-based domiciliary care provider Enara to listed trade player Mitie for £111m.
Sudinnova invests in EyeBrain
Sudinnova Capital has partaken in a €3.3m second round of funding for French biotech company EyeBrain.
TCR invests in In'Tech Medical
TCR Capital has acquired a stake in French orthopaedic devices manufacturer In'Tech Medical, alongside Arkea Capital.
MTI Ventures and Spark back BiOxyDyn with £1.2m
Medical imaging firm BiOxyDyn has secured capital commitments totalling £1.2m from Spark Impact and MTI Ventures.
NBGI's Praticdose to merge with Cima
NBGI Private Equity has completed the bolt-on acquisition of French healthcare equipment provider Cima, which will be merged with Praticdose.
Seventure's Biophytis secures €2m B-round funding
Seventure Partners and CM-CIC Capital Privé have joined new investor Metabrain Research in a €2m series-B financing round for French pharmaceuticals company Biophytis.
Seventure's Biophytis secures €2m B-round funding
Seventure Partners and CM-CIC Capital Privé have joined new investor Metabrain Research in a €2m series-B financing round for French pharmaceuticals company Biophytis.
YFM in £3m round for ImmunoBiology
YFM Equity Partners has contributed £900,000 as part of a £3m funding round for Cambridge-based biotech firm ImmunoBiology.
Apax's Mann leaves, replaced by healthcare co-head
Senior healthcare deal-maker Khawar Mann has left Apax Partners to join Russian clinics group Medsi.
Asclepios backs Genmedica with €12m
Life sciences-focused VC Asclepios Bioresearch has invested €12m in Spanish biotech firm Genmedica Therapeutics.
August Equity appoints investment director
UK-based private equity house August Equity has hired Stuart Quin as an investment director to focus primarily on the healthcare sector.
AXA PE buys Limacorporate stake
AXA Private Equity and banking group Intesa Sanpaolo have acquired a 66% stake in orthopaedic devices producer Limacorporate.
Advent to take Mediq private for €775m
Advent International has announced plans to delist Dutch pharma company Mediq from the Euronext Amsterdam, valuing the company at €775m.
Spark backs Molplex with £350,000
Spark Impact has invested £350,000 into drug discovery company Molplex.
Wellington Partners IV holds €70m first close
Wellington Partners has held a first closing for Wellington Partners IV Life Science on €70m.
Medical technology: Healthcare's third way
In between the hotly sought after healthcare services market and the much watched pharmaceuticals niche sits an elusive sub-sector. What has become of the UK medical technology and supplies sector?
Inveready in €1m round for AB Therapeutics
Inveready has taken part in a €1m funding round for Spanish pharmaceuticals firm AB Therapeutics.
Spanish VCs back ForMune with €4.4m
Venture capital firms Inveready and Caja Navarra, alongside public company Navarra Development Society (Sodena), have supported the spinout of biotech firm ForMune from parent company Digna Biotech with a capital commitment of €4.4m over the next three...
Sovereign's City & County in 10th acquisition
Sovereign Capital-backed City & County Healthcare Group has acquired Conard Care Services, a Northern Irish domiciliary care provider, in its 10th bolt-on since 2009.
SV Life Sciences et al. in $7.6m series-B for Karus
Karus Therapeutics has secured a $7.6m series-B financing round, led by SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust.